
Please try another search
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Name | Age | Since | Title |
---|---|---|---|
Michael D. Webb | - | 2022 | Director |
Frank Pasqualone | - | 2022 | Director |
Bevin O'Neil | - | 2022 | Director |
Michael D. Webb | 64 | 2022 | Independent Chairman of the Board |
George A. Kegler | 67 | 2020 | Independent Non-Employee Director |
Joseph Edward Tucker | 55 | 2021 | CEO & Director |
Marcus Schabacker | 59 | 2020 | Independent Non-Employee Director |
John H. Krystal | - | 2022 | Member of Scientific Advisory Board |
Sheila DeWitt | 62 | 2022 | Member of Scientific Advisory Board |
Michael B. Liebowitz | - | 2022 | Member of Scientific Advisory Board |
Frank Pasqualone | 67 | 2022 | Independent Director |
Maurizio Fava | - | 2022 | Chairman of Scientific Advisory Board |
Stephen M. Stahl | - | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review